Results 91 to 100 of about 22,288 (223)

Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.

, 2016
PURPOSE To identify the prevalence and progression of macular atrophy (MA) in neovascular age-related macular degeneration (AMD) patients under long-term anti-vascular endothelial growth factor (VEGF) therapy and to determine risk factors. METHOD
Wolfgang Huf, Martin S. Zinkernagel, Ceklic, Lala, Sebastian Wolf, Lala Ceklic, Munk, Marion, Zinkernagel, Martin, Huf, Wolfgang, Marion R. Munk, Andreas Ebneter, Ebneter, Andreas, Wolf, Sebastian   +11 more
core   +1 more source

An update on the pharmacotherapy of neovascular age-related macular degeneration

Expert Opinion on Pharmacotherapy, 2013
Neovascular age-related macular degeneration (AMD) is currently the most common cause of legal blindness in industrialized countries. The advent of pharmacotherapy with intravitreal VEGF inhibitors has greatly improved outcomes for the treatment of this disease.The present review is divided into two major sections: the period prior to the use of anti ...
Freund KB, Mrejen S, Gallego-Pinazo R
openaire   +3 more sources

MFGE8 does not influence chorio-retinal homeostasis or choroidal neovascularization in vivo

, 2012
Purpose: Milk fat globule-epidermal growth factor-factor VIII (MFGE8) is necessary for diurnal outer segment phagocytosis and promotes VEGF-dependent neovascularization.
David-Alexandre Tregouet (4350982), Florian Sennlaub (64439), Xavier Guillonneau, William Raoul (64427), Sophie Krumeich (177422), Sophie Krumeich, Raoul William, Théry Clotilde, Calippe Bertrand, Salomon-Yves Cohen, Poupel Lucie, Camelo, Serge, Xavier Guillonneau (64430), Bertrand Calippe, Behar-Cohen Francine, Tregouet, David-Alexandre, Baatz, Holger, Bertrand Calippe (177425), Florian Sennlaub, Lucie Poupel, Francine Behar-Cohen, Théry, Clotilde, Sophie Lavalette (64428), Serge Camelo (177419), Calippe, Bertrand, Cohen Salomon-Yves, Lavalette Sophie, Behar-Cohen, Francine, Clotilde Théry (177438), Lavalette, Sophie, Tregouet David-Alexandre, Christophe Combadière, Combadière Christophe, Raoul, William, William Raoul, Sennlaub Florian, Salomon-Yves Cohen (177429), Baatz Holger, Guillonneau, Xavier, Nicole Keller, Keller, Nicole, Guillonneau Xavier, Camelo Serge, Nicole Keller (64429), Keller Nicole, Cohen, Salomon-Yves, David-Alexandre Tregouet, Serge Camelo, Sophie Lavalette, Holger Baatz (177431), Krumeich Sophie, Christophe Combadière (177434), Sennlaub, Florian, Combadière, Christophe, Poupel, Lucie, Krumeich, Sophie, Lucie Poupel (177410), Holger Baatz, Clotilde Théry, Francine Behar-Cohen (64434)   +59 more
core   +1 more source

Interobserver variability for retreatment indications after Ranibizumab loading doses in neovascular age-related macular degeneration

, 2012
To assess the interobserver variability (IOV) in indicating retreatment for neovascular Age-related macular degeneration 4 weeks after three Ranibizumab loading doses using spectral domain OCT (SD-OCT) as the primary objective diagnostic ...
Walter, Andreas, Gamulescu, Maria Andreea, Framme, Carsten, Helbig, Horst, Panagakis, Georgios, Herrmann, Wolfgang   +5 more
core   +1 more source

Current perspectives on ranibizumab

Clinical Ophthalmology, 2015
Vaidehi S Dedania,1 Sophie J Bakri21Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY, USA; 2Department of Ophthalmology, Mayo Clinic, Rochester, MN, USABackground: This review summarizes the Phase III studies addressing
Dedania VS, Bakri SJ
doaj  

Treatment of neovascular age-related macular degeneration: Current therapies

Clinical Ophthalmology, 2009
Albert J Augustin, Stefan Scholl, Janna KirchhofDepartment of Ophthalmology, Klinikum Karlsruhe, GermanyAbstract: Choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) is now the leading cause of blindness and severe ...
Albert J Augustin, Stefan Scholl, Janna Kirchhof   +2 more
doaj  

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment

, 2018
Pear Pongsachareonnont,1,2 Michael Ying Kit Mak,2 Cameron Paul Hurst,3 Wai-Ching Lam2,4 1Vitreo-Retinal Research Unit, Department of Ophthamology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross ...
Pongsachareonnont P, Hurst CP, Lam WC, Mak MYK   +3 more
core  

Real World Data Comparison of Standard Care vs SDM Laser Vision Protection Therapy for Prevention of Neovascular AMD

Clinical Ophthalmology, 2022
Jeffrey K Luttrull,1 Gerry Gray2 1Ventura County Retina Vitreous Medical Group, Ventura, CA, USA; 2Regulatory Pathways, Inc, Laguna Beach, CA, USACorrespondence: Jeffrey K Luttrull, Ventura County Retina Vitreous Medical Group, 3160 Telegraph Road, Suite
Luttrull JK, Gray G
doaj  

Ranibizumab versus verteporfin for neovascular age-related macular degeneration

, 2006
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic ...
ANCHOR, Study Group, Brown, DM, Kaiser, PK, Soubrane, G, Michels, M, Schneider, S, Heier, JS, Kim, RY, Sy, JP   +8 more
core   +1 more source

Long-Term Follow-Up of Dry Age-Related Macular Degeneration Patients

Journal of Current Ophthalmology
Purpose: To assess the progression rate from dry age-related macular degeneration (dAMD) to advanced AMD and possible risk factors. Methods: Demographics, medical and ocular conditions, baseline eye examinations, optical coherence tomography features ...
Elham Sadeghi, Golnoush Mahmoudinezhad, Nicola Valsecchi, Sharat Chandra Vupparaboina, Sandeep Chandra Bollepalli, Kiran Kumar Vupparaboina, Jose-Alain Sahel, Andrew W. Eller, Jay Chhablani   +8 more
doaj   +1 more source